NCT00343109View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

June 30, 2015

Conditions
HER2-positive Breast CancerMale Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
BIOLOGICAL

HER-2/neu intracellular domain protein

Given ID

PROCEDURE

leukapheresis

Optional correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

BIOLOGICAL

sargramostim

Given ID

OTHER

immunologic technique

Correlative studies

BIOLOGICAL

synthetic tumor-associated peptide vaccine therapy

Given ID

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT00343109 - Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer | Biotech Hunter | Biotech Hunter